In This Article:
JPMorgan downgraded Pliant Therapeutics (PLRX) to Neutral from Overweight without a price target after the company announced a voluntary pause to the enrollment, and dosing, of its Phase 2b BEACON trial based on the recommendation of the Data and Safety Monitoring Board. The news “portends a material fundamental setback for the program, either for reasons of safety or futile activity,” the analyst tells investors in a research note. The firm says that with little pipeline value beyond bexotograst, it sees share downside to $3-$4 on the update, in line with the company’s year-end estimated cash. The stock in premarket trading is down 60%, or $4.780, to $3.09.
Maximize Your Portfolio with Data Driven Insights:
-
Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
-
Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PLRX: